Oslo Pensjonsforsikring AS Purchases Shares of 4,648 Gilead Sciences, Inc. $GILD

Oslo Pensjonsforsikring AS bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the first quarter, according to the company in its most recent filing with the SEC. The firm bought 4,648 shares of the biopharmaceutical company’s stock, valued at approximately $648,000.

Other hedge funds have also added to or reduced their stakes in the company. Aviva PLC boosted its stake in Gilead Sciences by 5.4% in the 4th quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company’s stock worth $141,978,000 after purchasing an additional 59,782 shares in the last quarter. Life Cycle Investment Partners Ltd bought a new stake in Gilead Sciences during the 4th quarter valued at about $1,418,000. Beacon Investment Advisory Services Inc. increased its stake in Gilead Sciences by 10.3% during the 4th quarter. Beacon Investment Advisory Services Inc. now owns 111,531 shares of the biopharmaceutical company’s stock valued at $13,689,000 after purchasing an additional 10,449 shares in the last quarter. NBC Securities Inc. raised its holdings in Gilead Sciences by 150.3% in the fourth quarter. NBC Securities Inc. now owns 17,147 shares of the biopharmaceutical company’s stock worth $2,105,000 after buying an additional 10,296 shares during the last quarter. Finally, Exchange Traded Concepts LLC lifted its stake in shares of Gilead Sciences by 45.7% in the fourth quarter. Exchange Traded Concepts LLC now owns 243,532 shares of the biopharmaceutical company’s stock worth $29,891,000 after buying an additional 76,432 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $130.28 on Wednesday. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The company has a 50 day moving average price of $129.63 and a 200-day moving average price of $135.42. Gilead Sciences, Inc. has a 52 week low of $108.06 and a 52 week high of $157.29. The firm has a market capitalization of $161.75 billion, a PE ratio of 17.75 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter in the prior year, the firm earned $1.81 earnings per share. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities research analysts expect that Gilead Sciences, Inc. will post -0.77 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date was Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $126.29, for a total value of $1,894,350.00. Following the transaction, the chief executive officer directly owned 607,133 shares of the company’s stock, valued at approximately $76,674,826.57. This trade represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the sale, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at $21,524,408.40. The trade was a 1.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 77,000 shares of company stock valued at $9,978,740 over the last 90 days. Company insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Daiwa Securities Group cut their price target on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, May 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 price objective on shares of Gilead Sciences in a research report on Monday, July 6th. Citigroup increased their target price on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Weiss Ratings lowered Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, May 28th. Finally, Leerink Partners cut Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $146.00 to $127.00 in a research note on Tuesday. Twenty-five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $158.33.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.